KLF9: A Potential Drug Target and Biomarker (G687)

Target Name: KLF9

NCBI ID: G687

KLF9

KLF9: A Potential Drug Target and Biomarker

Krueppel-like factor 9 (KLF9) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential as a drug.

KLF9: Structure and Function

KLF9 is a small RNA molecule that contains 239 amino acid residues. It has a characteristic structure that is similar to that of microRNAs, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. MicroRNAs are derived from mRNAs through a process called exon exclusion, which results in the creation of small, non-coding RNAs that are targeted for degradation by the 26S rRNA complex.

KLF9 is expressed in various tissues and cells, including the brain, heart, and pancreas, and has been shown to play a role in various physiological processes. For example, KLF9 has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion, as well as in the regulation of inflammation and immune responses.

KLF9 as a Drug Target

KLF9 has been identified as a potential drug target due to its unique structure and the diseases it is associated with. One of the most promising aspects of KLF9 is its role in cancer, as it has been shown to be involved in the regulation of tumor growth and the development of cancer cell metastases.

Studies have shown that KLF9 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to cancer cells.

In addition to its role in cancer, KLF9 has also been shown to be involved in a variety of other diseases, including neurodegenerative diseases and metabolic disorders. For example, KLF9 has been shown to play a role in the regulation of dopamine synthesis and uptake in the brain, as well as in the regulation of insulin sensitivity in obesity.

KLF9 as a Biomarker

KLF9 has also been shown to be a potential biomarker for a variety of diseases. For example, KLF9 has been shown to be involved in the regulation of cancer cell proliferation, and has been used as a biomarker for cancer diagnosis and prognosis.

Studies have shown that KLF9 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to cancer cells.

In addition to its role in cancer, KLF9 has also been shown to play a role in a variety of other diseases, including neurodegenerative diseases and metabolic disorders. For example, KLF9 has been shown to play a role in the regulation of dopamine synthesis and uptake in the brain, as well as in the regulation of insulin sensitivity in obesity.

Conclusion

KLF9 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential as a drug. Further research is needed to fully understand the role of KLF9 in various diseases and to develop effective treatments.

Protein Name: KLF Transcription Factor 9

Functions: Transcription factor that binds to GC box promoter elements. Selectively activates mRNA synthesis from genes containing tandem repeats of GC boxes but represses genes with a single GC box. Acts as an epidermal circadian transcription factor regulating keratinocyte proliferation (PubMed:22711835)

The "KLF9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets